Neumora Therapeutics (NASDAQ:NMRA), headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.
Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders. By leveraging translational neuroscience platforms and robust in vivo and in vitro models, Neumora seeks to identify and validate new molecular targets, optimize lead candidates and de-risk clinical programs prior to human testing.
Founded in 2020 with backing from leading life sciences investors, Neumora has assembled a leadership team with deep expertise in neuroscience research, drug development and precision medicine. The executive team is led by President and Chief Executive Officer Jay A. Humphrey, who brings over two decades of experience in advancing CNS therapies, alongside a multidisciplinary group of scientists and drug developers drawn from biotechnology and pharmaceutical industry backgrounds.
Neumora’s research and development operations are based in the greater Boston area, with plans to expand collaborations and strategic partnerships both within the United States and internationally. With a commitment to rigorous translational science, the company aims to deliver next-generation treatments that improve outcomes for patients living with complex brain and nervous system disorders.
